Allergan Aesthetics secures European approval for rapid-onset botulinum toxin E

Leading pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced that they have received approval from the European Commission for trenibotulinumtoxinE ‘Boey’.

This marks the first botulinum neurotoxin serotype E approved in Europe for the temporary improvement of moderate to severe glabellar lines in adults.

The approval follows the completion of the centralised European regulatory procedure and applies across all 30 countries within the European Economic Area (EEA). It comes shortly after Boey was approved in Canada in June.

Allergan have stated that Boey is the first and only rapid-onset, short-duration botulinum toxin of its kind available in Europe. Clinical studies demonstrated an onset of effect as early as eight hours after treatment, with results lasting between two and three weeks.

Darin Messina, Ph.D., senior vice president, aesthetics research & development at AbbVie, said: “The EU approval of Boey® marks an important step forward for our development program and builds on the momentum we’ve established with Health Canada’s approval earlier this year. This milestone reflects the scientific rigor behind Boey and reinforces our commitment to advancing innovative options as we work to bring this first-of-its-kind treatment to healthcare professionals and consumers around the world.”

Allergan Aesthetics says Boey has been developed to address this demand, offering suitable patients the opportunity to experience the effects of botulinum toxin treatment with a shorter duration before deciding whether to pursue longer-lasting neurotoxin treatments.